Evidence map›Paper›PMID 40677571›Full record

ReviewWorld journal of gastrointestinal endoscopy2025

Endoscopic insights into digestive-related adverse effects of immune checkpoint inhibitors: A narrative review.

Grigorios Petrousis, Sylwester Szczegielniak, Haider Sabhan, Peter Elbe, Gülden Bilican, Hans Strid, Francesca Bresso, Charlotte Hedin, Stephan L Haas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Grigorios PetrousisCentre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm 17164, Sweden.
Sylwester SzczegielniakCentre for Digestive Health, Division of Endoscopy, Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm 17164, Sweden.
Haider SabhanDepartment of Medicine Solna, Karolinska Institutet, Stockholm 17164, Sweden.
Peter ElbeCentre for Digestive Health, Division of Endoscopy, Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Stockholm 17164, Sweden.
Gülden BilicanDepartment of Gastroenterology, Gazi University, Faculty of Medicine, Ankara 06, Türkiye.
Hans StridCentre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm 17164, Sweden.
Francesca BressoCentre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm 17164, Sweden.
Charlotte HedinCentre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm 17164, Sweden.
Stephan L HaasCentre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm 17164, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment with immune checkpoint inhibitors (ICIs) is an innovative therapy for managing certain types of malignancy and has the potential to improve overall patient survival significantly. The most widely used ICIs selectively target different receptors comprising programmed cell death-1 receptor, programmed cell death-ligand 1 receptor, and cytotoxic T lymphocyte antigen 4 receptor. The widespread utilization of ICIs over the past several years, however, is frequently accompanied by immune-related adverse events (irAEs) that substantially impact the patient's quality of life, particularly those affecting the digestive system, including both the upper and lower gastrointestinal tract. Based on a literature search covering databases such as PubMed, Web of Science, Embase, and the Cochrane Library, we present an insight into primary gastrointestinal irAEs, with a special focus on endoscopic manifestations. Additionally, we analyze data regarding the pathogenetic mechanisms, diagnostic approaches, histological characteristics, and proposed therapeutic interventions for managing irAEs involving the gastrointestinal tract.

Indexed as

ColitisEndoscopyEnteritisGastritisGastrointestinal tractImmune checkpoint inhibitorsImmune-related adverse eventsToxicity

Identifiers

PMID40677571
PMCPMC12264759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.